Related Experiment Videos

Optimizing thiadiazole analogues of resveratrol versus three chemopreventive targets

Abdelrahman S Mayhoub1, Laura Marler, Tamara P Kondratyuk

  • 1Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy and the Purdue Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA.

Bioorganic & Medicinal Chemistry
|November 26, 2011
PubMed

Insights

Researchers developed novel chemopreventive agents by modifying resveratrol. These new compounds show improved potency and selectivity in inhibiting cancer-promoting pathways and boosting cancer-preventive enzymes.

Area of Science:

  • Medicinal Chemistry
  • Cancer Research
  • Pharmacology

Background:

  • Chemoprevention aims to reduce cancer incidence and mortality by inhibiting carcinogenesis.
  • Resveratrol, a trans stilbene derivative, exhibits chemopreventive properties but suffers from weak, non-specific biological activity.
  • There is a need for more potent and selective chemopreventive agents.

Purpose of the Study:

  • To design and synthesize novel chemopreventive agents with enhanced potency and selectivity.
  • To evaluate the efficacy of these agents as inhibitors of aromatase and NF-κB.
  • To assess their potential as inducers of quinone reductase 1 (QR1).

Main Methods:

  • Chemical synthesis involving the replacement of resveratrol's ethylenic bridge with a 1,2,4-thiadiazole heterocycle.
  • Modification of substituents on the aromatic rings of the resveratrol scaffold.
  • In vitro evaluation of synthesized compounds as inhibitors of aromatase and NF-κB, and as inducers of QR1.

Main Results:

  • The novel thiadiazole-based compounds demonstrated enhanced potency compared to resveratrol.
  • These agents exhibited improved selectivity in their biological targets.
  • The modified compounds effectively inhibited aromatase and NF-κB, and induced QR1.

Conclusions:

  • Replacing resveratrol's ethylenic bridge with a 1,2,4-thiadiazole heterocycle yields potent chemopreventive agents.
  • Structural modifications enhance selectivity and efficacy against key cancer-related targets.
  • These novel compounds represent promising candidates for further development in cancer chemoprevention.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...